Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Mr. Miller who wrote (1386)	11/12/1998 3:08:00 PM
From: Mr. Miller	Read Replies (1) \| Respond to of 2135

A company with 13 million shares may be sitting on the best therapy for cancer today. Can you imagine the sales? I am glad it will help people obviously, but the sales will be incredible. Miller

To: Mr. Miller who wrote (1386)	11/12/1998 5:09:00 PM
From: LTK007	Read Replies (1) \| Respond to of 2135

Mr Miller I going to study carefully the WSJ article--because if it is erroneous science from those trying to duplicate results---this could be create a real buying opportunity---now it should be known Folkman has many enemies in his field---so one must evalute the objectivity of the naysayers--but I am not buying until I can get a feel for which side is right---but like you say,Entremed has NCI backing--Max

To: Mr. Miller who wrote (1386)	11/12/1998 8:32:00 PM
From: Orwell	Read Replies (1) \| Respond to of 2135

ENMD response offered nothing, I would have thought that they would come out with both guns blazing. Reminded me of the Bre-X saga where the Bre-X gold explorers said that other geologists couldn't reproduce the same test results because they weren't familiar with the special nature of the soil and geologic-formations of that part of Indonesia. Baloney! I still like the theories behind ENMD's science though, and will be closely following it as an investment candidate, but I don't invest in any biotechs until they are in Phase III, just like not buying junior gold explorers until a senior company has verified the results and feasability studies. O.